OSR Holdings, Inc. (NASDAQ:OSRH) Sees Large Growth in Short Interest

OSR Holdings, Inc. (NASDAQ:OSRH) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totaling 916,507 shares, a growth of 143.1% from the March 15th total of 376,966 shares. Based on an average daily volume of 1,490,249 shares, the days-to-cover ratio is presently 0.6 days. Approximately 7.0% of the company’s stock are sold short.

Institutional Investors Weigh In On OSR

An institutional investor recently bought a new position in OSR stock. Susquehanna International Group LLP acquired a new stake in OSR Holdings, Inc. (NASDAQ:OSRH) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned about 0.37% of OSR at the end of the most recent quarter. Institutional investors and hedge funds own 55.30% of the company’s stock.

OSR Stock Up 0.8%

NASDAQ:OSRH opened at $0.54 on Tuesday. OSR has a twelve month low of $0.38 and a twelve month high of $1.79. The business has a 50 day moving average price of $0.48 and a two-hundred day moving average price of $0.58. The company has a market cap of $17.86 million, a P/E ratio of -0.42 and a beta of 0.59.

Analysts Set New Price Targets

Several brokerages recently issued reports on OSRH. Weiss Ratings reiterated a “sell (e+)” rating on shares of OSR in a research report on Friday, March 27th. Wall Street Zen lowered OSR from a “sell” rating to a “strong sell” rating in a research report on Sunday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, OSR has a consensus rating of “Sell”.

OSR Company Profile

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.